Answers are grounded in this paper and cite their sources.
To evaluate the safety and efficacy of CBT-001, a multitarget tyrosine kinase inhibitor eyedrop, for pterygia.
No takes yet. Share an insight, caveat, or question.
Whitcup et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: